Thus, while the single-agent kinase inhibitor treatment promotes the recruitment of tumor-infiltrating lymphocytes only the combination with a RIG-I agonist effectively promotes the clearance of drug-tolerant persisters. This evidence concerns the gene RIGI and neoplasm.